SRR8518351
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.410
- WNT_BETA_CATENIN_SIGNALING+0.400
- APICAL_SURFACE+0.320
- IL6_JAK_STAT3_SIGNALING+0.250
- ALLOGRAFT_REJECTION+0.240
- MYOGENESIS+0.170
- APICAL_JUNCTION+0.150
- INFLAMMATORY_RESPONSE+0.130
- IL2_STAT5_SIGNALING+0.100
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- OXIDATIVE_PHOSPHORYLATION-0.450
- MYC_TARGETS_V1-0.430
- MTORC1_SIGNALING-0.420
- CHOLESTEROL_HOMEOSTASIS-0.370
- ANDROGEN_RESPONSE-0.330
- FATTY_ACID_METABOLISM-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
- UV_RESPONSE_DN-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A441-01A-11R-A24H-07 | — | D | 0.838 |
| 2 | MNG1096 | — | — | 0.835 |
| 3 | C3N-02675 | — | cohortSQ1 | 0.831 |
| 4 | SRR12202481 | — | — | 0.831 |
| 5 | SRR8613797 | — | D | 0.828 |
| 6 | AUR-AFR5-TTP1-A-1-1-R-A743-41 | — | D | 0.826 |
| 7 | SRR8518409 | — | D | 0.821 |
| 8 | MBCProject_0582_T1_RNA | — | D | 0.812 |
| 9 | s_150324_1b | EPN | Supratentorial EPN | 0.804 |
| 10 | TCGA-LD-A7W5-01A-22R-A352-07 | — | A | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |